PanOmiQ Set’s New Benchmark with 100% Accuracy in Whole Genome Sequencing Testing
20. August 2024 09:48 ET
|
BioAro
BioAro's PanOmiQ achieves 100% accuracy in Whole Genome Sequencing, setting a new benchmark; a 15-day free trial of AI-powered software is now available.
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
29. Juli 2024 08:30 ET
|
Palisade Bio, Inc.
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of...
Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024
23. Januar 2024 09:00 ET
|
Baylor Genetics
Showcase Presentation to Include Case Examples from NIH’s Undiagnosed Diseases Network (UDN)
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
28. September 2023 15:48 ET
|
Telesis Bio
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp®...
Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States
09. August 2021 07:39 ET
|
Dante Labs
CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member. Mark is...
Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy
19. Juli 2021 07:07 ET
|
Dante Labs
Bob Ragusa leads Illumina global operations and is a key contributor to Illumina's growth and global scaling.Dante Labs integrated precision medicine offering leverages the intersection of local lab...
Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients
08. Juli 2021 04:00 ET
|
Dante Labs
Stripe2be uses an unbiased approach to Whole Genome Sequencing (WGS) for rare diseases: combining the information submitted from both personal patient records and statements, and using the Dante Labs...
ProPhase Labs Diversifies with Formation of Genomics and Global Healthcare Subsidiaries
10. Juni 2021 08:30 ET
|
ProPhase Labs, Inc.
ProPhase Precision Medicine, Inc. and ProPhase Global Healthcare, Inc. to Expand Opportunities in Genomics and International Testing Services ProPhase Diagnostics, Inc. Developing New Testing...